Navigation Links
Abatacept as effective as adalimumab in rheumatoid arthritis
Date:6/12/2013

Madrid, Spain, 12 June 2013: Data from AMPLE presented at EULAR 2013, the Annual Congress of the European League Against Rheumatism, demonstrate comparable efficacy and similar safety profiles between subcutaneous abatacept (ABA) and adalimumab (ADA).

AMPLE, the first two-year head-to-head biologics trial, was comprised of 646 biologic-nave patients with active rheumatoid arthritis (RA) equally randomised to either ABA or ADA, with a stable dose of methotrexate (MTX). 79.2% (252 of 318) ABA patients and 74.7% (245 of 328) ADA patients completed the trial.

RA is a chronic autoimmune disease that principally attacks flexible joints. Affecting approximately 1 in 100 people worldwide, RA can cause pain, stiffness, progressive joint destruction and deformity, and reduce physical function, quality of life and life expectancy. At least 50% of RA patients in developed countries are unable to hold down a full-time job within 10 years of onset.2

"To date, there have been no randomised, controlled studies directly comparing the efficacy and safety of different biological DMARDs using the combination of a biologic medication and methotrexate, the most commonly prescribed treatment approach in moderate to severe RA", said lead author of the study Dr. Michael Schiff, University of Colorado, USA.

"This robust data set demonstrates that subcutaneous abatacept and adalimumab are equally efficacious in clinical, functional and radiographic outcomes. This study is a great leap forward for patients as it shows another treatment is as effective as adalimumab" Dr. Schiff concluded.

AMPLE is a Phase IIIb randomised, investigator-blinded study with a primary efficacy endpoint at day 365. Biologic-nave patients with active RA and an inadequate response to MTX were randomized to 125 mg ABA weekly (without an IV load) or 40 mg ADA bi-weekly, with a stable dose of MTX. All clinical efficacy endpoints were captured and read through day 729, including radiographs assessed using the van der Heijde modified Total Sharp score (mTSS), by readers blinded to treatment allocation and sequence.

At Year one, 64.8% ABA and 63.4% ADA patients were ACR20* responders. Consistent with Year one, clinical efficacy measures and inhibition of radiographical progression were comparable between groups at Year two. There were similar rates of adverse events (AE) and serious adverse events (SAE) in the ABA and ADA groups (13.8% vs. 16.5%) and malignancies (2.2% vs. 2.1%). More autoimmune AEs occurred in the ABA arm (3.8% vs. 1.8%); none were SAEs. Injection site reactions occurred less frequently in the ABA arm (4.1% vs. 10.4%). There were fewer discontinuations due to adverse events (3.8% vs. 9.5%), serious adverse events (1.6% vs. 4.9%), and due to serious infections (0/12 vs. 9/19 patients) in the ABA vs. ADA groups, respectively.

Abatacept (Orencia), produced by Bristol-Myers Squibb, is a first-in-class biologic which reduces co-stimulation of T-cells, in turn reducing activation of other cells in the inflammatory process, blocking the pain, inflammation and joint progression pathways in RA.

Adalimumab (Humira), produced by Abbott, is a biologic TNF-blocker (anti-TNF). Adalimumab binds to TNF-alpha receptors, blocking the pain, inflammation and joint progression pathways in RA.


'/>"/>

Contact: EULAR Press Office
eularpressoffice@cohnwolfe.com
44-020-733-15364
European League Against Rheumatism
Source:Eurekalert

Related medicine news :

1. Head-to-head study in RA shows that abatacept has comparable efficacy to adalimumab
2. Daimer Offers Steam Cleaner Vacuums for Effective Restroom Cleaning in Commercial Settings
3. The Fight Against West Nile Virus Begins Again: Learn Simple, Effective Tips to Protect Yourself and Family
4. PET/MR effective for imaging recurrent prostate cancer
5. Rihanna Herpes and Lipstick Fiasco Shows Need for Effective Herpes Remedy; polyDNA Recommends Gene-Eden-VIR to Kill Latent Herpes Virus
6. Screening at-risk adolescents for celiac disease proves cost-effective
7. 2013 Report Confirms Effective Cyber Emergency Response Plan is Vital to Slash Data Breach Costs
8. hCGTreatments / Diet Doc hCG Diets & Weight Loss Plans Offer New, Advanced Weight Loss Tips to Rapidly Reduce Weight and Increase Effective Stress Management
9. Everyday Vitamin Nutrition LLC Offers Most Potent and Effective Garcinia Cambogia for Appetite Suppression
10. African Mango Plus is Clinically Proven Effective Formula to Increase the Energy Level of the Body
11. ZetaClear the 2-Step Natural Formula is Now Available to Effectively Fight Against the Nail Fungus
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... June 25, 2016 , ... On Friday, June 10, Van Mitchell, Secretary of ... award to iHire in recognition of their exemplary accomplishments in worksite health promotion. , ... Workplace Health & Wellness Symposium at the BWI Marriott in Linthicum Heights. iHire was ...
(Date:6/24/2016)... ... 24, 2016 , ... June 19, 2016 is World Sickle Cell Observance Day. ... the benefits of holistic treatments, Serenity Recovery Center of Marne, Michigan, has ... , Sickle Cell Disease (SCD) is a disorder of the red blood cells, which ...
(Date:6/24/2016)... , ... June 24, 2016 , ... ... offering micro-osteoperforation for accelerated orthodontic treatment. Dr. Cheng has extensive experience with all ... brackets , AcceleDent, and accelerated osteogenic orthodontics. , Micro-osteoperforation is a revolutionary ...
(Date:6/24/2016)... Georgia (PRWEB) , ... June 24, 2016 , ... ... awards today at the Clinical Decision Making in Emergency Medicine conference in Ponte ... have authored journal articles published in Emergency Medicine Practice and Pediatric ...
(Date:6/24/2016)... ... June 24, 2016 , ... National recruitment firm Slone Partners is ... sequencing and genomics experience, as Vice President of North American Capital Sales at ... for leading the sales team in the commercialization of the HTG EdgeSeq system and ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)... Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) announced ... Act of 1976, as amended ("HSR"), with respect to ... CPXX ) expired effective June 24, 2016, ... previously announced on May 31, 2016, Jazz Pharmaceuticals and ... Jazz Pharmaceuticals has commenced a tender offer for all ...
(Date:6/24/2016)...  Collagen Matrix, Inc., ("Collagen Matrix") the driving ... collagen and mineral based medical devices for tissue ... Messer has joined the company as Vice ... growing portfolio of oral surgery, neurosurgery, orthopaedic and ... the Collagen Matrix executive team as an accomplished ...
(Date:6/24/2016)... DUBLIN , June 24, 2016 ... addition of the "Structural Electronics 2015-2025: Applications, ... In-Mold Electronics, Smart ... Integrated Photovoltaics Structural electronics involves ... as load-bearing, protective structures, replacing dumb structures such ...
Breaking Medicine Technology: